A number of other research analysts have also commented on PBYI. Vetr lowered shares of Puma Biotechnology from a strong-buy rating to a buy rating and set a $40.36 price objective for the company. in a research report on Monday, May 30th. Zacks Investment Research lowered shares of Puma Biotechnology from a hold rating to a sell rating in a research report on Tuesday, June 7th. Credit Suisse Group AG reissued a buy rating on shares of Puma Biotechnology in a research report on Tuesday, July 12th. Stifel Nicolaus reissued a hold rating on shares of Puma Biotechnology in a research report on Sunday, July 24th. Finally, Citigroup Inc. set a $88.00 price target on shares of Puma Biotechnology and gave the stock a buy rating in a research report on Tuesday, September 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $68.56.
Puma Biotechnology (NYSE:PBYI) opened at 69.68 on Thursday. The stock’s 50 day moving average price is $56.97 and its 200 day moving average price is $39.86. Puma Biotechnology has a 12 month low of $19.74 and a 12 month high of $94.93. The firm’s market capitalization is $2.26 billion.
Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.18) by $1.01. On average, analysts forecast that Puma Biotechnology will post ($8.12) earnings per share for the current year.
Hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas boosted its stake in shares of Puma Biotechnology by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 465 shares in the last quarter. Legal & General Group Plc boosted its stake in Puma Biotechnology by 142.4% in the second quarter. Legal & General Group Plc now owns 6,142 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 3,608 shares during the period. Quantbot Technologies LP bought a new stake in Puma Biotechnology during the second quarter valued at approximately $183,000. Canada Pension Plan Investment Board boosted its stake in Puma Biotechnology by 71.8% in the first quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 2,800 shares during the period. Finally, Fiera Capital Corp bought a new stake in Puma Biotechnology during the second quarter valued at approximately $232,000. 97.53% of the stock is currently owned by hedge funds and other institutional investors.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.
Receive News & Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.